Document Classification

Section Type: RESULTS

Text: Oxymorphone ER 40 and 50 mg produced significant improvements from baseline compared with placebo in the WOMAC subscale scores for pain (least squares mean change : -85. 1, -108. 0, and -42. 5, respectively ; P < or = 0. 025 for 40 mg, P < or = 0. 001 for 50 mg), stiffness (-40. 5, -48. 1, and -17. 0 ; both, P < or = 0. 001), and physical function (-256. 8, -310. 8, and -116. 5 ; P < or = 0. 01 and P < or = 0. 001, respectively) ; the SF-36 PCS score (4. 6, 3. 6, and -0. 1 ; P < 0. 001) ; and the CPSI score (-21. 2, -22. 2, and -10. 7 ; P < 0. 05).